Brainspotting
Brainspotting (BSP)
Evidence grade varies by use. See the breakdown on the entry. Read how the Atlas grades evidence.
Evidence is limited and preliminary. The published base is small and dominated by pilot studies, single-case reports, and trials involving the method's originator or trainers, which raises allegiance-bias concerns. Hildebrand, Grand, and Stemmler (2017) reported a multinational naturalistic comparison in which Brainspotting reduced PTSD, depression, and anxiety symptoms comparably to EMDR; D'Antoni and colleagues (2022, Italy) reported that Brainspotting and EMDR each outperformed a body-scan and placebo condition, but used short single sessions with non-clinical participants. Independent, adequately powered, blinded randomized controlled trials in clinical populations are largely absent. The American Psychological Association does not list Brainspotting among its recommended PTSD treatments, and several reviewers characterize it as emerging at best and as fringe or unproven at worst. The honest read: early signals are not discouraging, but they do not yet establish efficacy, and the gap between the confident mechanistic story and the thin trial base is wide.
Reference only. Not medical advice.
| Treatment | Grade | Notes |
|---|---|---|
| PTSD / post-traumatic stress | 2 of 5 | A few small or naturalistic studies (e.g. Hildebrand 2017) report symptom reduction comparable to EMDR, but most involve the originator and lack independent blinded RCTs in clinical samples. |
| Anxiety and depression (as secondary outcomes) | 2 of 5 | Reductions reported alongside PTSD outcomes in the same originator-involved studies; no robust standalone trials. Treated as preliminary. |
| Proposed neurophysiological mechanism (eye position maps to a subcortical trauma site) | 1 of 5 | Theory outpaces evidence. No independent neuroscience confirms a discrete gaze-to-brain-location mapping; reviewers call the mechanism unvalidated and not clearly testable as stated. |
| Performance, creativity, and general 'expansion' uses promoted in trainings | 1 of 5 | Marketed applications well beyond the trauma evidence base; essentially no controlled support. |
What can go wrong
Generally low physical risk as delivered by a licensed clinician within their existing scope. The real risks are clinical, not somatic: accessing trauma material can trigger acute distress, dissociation, or destabilization, which is why it belongs in qualified hands rather than self-administration. Choosing Brainspotting over therapies with stronger evidence (such as trauma-focused CBT or prolonged exposure) is itself a risk for people with significant PTSD. Marketing that frames it as uniquely fast or able to reach what other therapies cannot can set up expectations the evidence does not support.
This is something to take to a clinician. The Atlas can tell you what is known about brainspotting in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Brainspotting is a trauma-focused psychotherapy created by David Grand in 2003, an offshoot of EMDR organized around a single vivid premise that proponents summarize as "where you look affects how you feel." A clinician helps a client find a "brainspot," an eye position in the visual field that, when held, is said to keep attention locked onto unprocessed trauma so it can move and resolve, often with bilateral sound playing underneath. The idea that a fixed gaze can change inner state is genuinely ancient and first documented not in the West but in India, in yogic trataka and drishti, though Brainspotting claims no descent from those traditions and arrived only this century. Many clients and clinicians describe meaningful relief, and a handful of small or naturalistic studies put it roughly on par with EMDR. The honest picture is narrower than the marketing: the trial base is thin, often run by the method's own originator, and the proposed brain mechanism has not been independently validated. The clinical promise is real enough to take seriously and far from proven, and the confident neuroscience story is the weakest part of the package.
A trauma therapy built on a single arresting idea, that where you fix your eyes changes what you feel, riding ahead of the science meant to test it.
How it is supposed to work
Established mechanism: none is confirmed. Proposed mechanism, as described by David Grand and proponents: a relevant eye position, the "brainspot," is said to correspond to and hold a neural site of unprocessed trauma in subcortical structures, with the midbrain and related deep regions invoked; maintaining gaze on that point is claimed to keep the brain focused on the stored material so it can be processed and discharged, often paired with bilateral "BioLateral" sound. Independent neuroscience has not validated that a fixed eye position maps to a discrete trauma-holding brain location, and reviewers note the proposed mechanism is not clearly testable as stated. What is plausible and shared with much of psychotherapy is nonspecific processing: focused attention, interoception, a regulating therapeutic relationship, and exposure to distressing material in a tolerable window.
What people get wrong
Often saidBrainspotting reaches trauma stored in the deep brain that talk therapy cannot touch, and science backs the mechanism.
ActuallyThe deep-brain storage and gaze-mapping claim is proposed by its developer, not independently validated, and reviewers note it is not clearly testable as stated.
Often saidIt is a proven, evidence-based PTSD treatment on par with established therapies.
ActuallyA few small or naturalistic studies suggest it may rival EMDR, but adequately powered independent randomized trials are largely missing, and the APA does not list it among recommended PTSD treatments.
Who profits, and who pushes back
David Grand, PhD
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Where you look affects how you feel; the brainspot lets us access and process trauma held in the subcortical brain that talk therapy struggles to reach.
Brainspotting trainers and certified practitioners
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Clinically we see consistent, often rapid relief, and comparison studies put it in the same range as EMDR.
Independent trauma clinicians
Some clients clearly respond, but the early benefit is hard to separate from attention, alliance, and exposure common to many therapies; treat it as promising, not proven.
Skeptical psychologists and reviewers
It lacks scientific credibility and a clear testable mechanism, and the APA does not list it as a recommended PTSD treatment; the marketing runs well ahead of the data.
Where the research comes from
Most of the published research on this comes from one place. 85% of it is from United States. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| United States | 85% |
| Germany / German-speaking Europe | 55% |
| Latin America (esp. Brazil) | 45% |
| United Kingdom and Ireland | 35% |
| Australia | 25% |
How we got here
The practice of fixing the gaze on a single point to shift inner state is documented first in India, not the West. Classical Hatha Yoga manuals such as the Hatha Yoga Pradipika (roughly 15th century) and the Gheranda Samhita name trataka, steady unblinking gazing at a small mark, candle flame, or yantra, among the six shatkarma cleansing techniques, and the related concept of drishti, directed yogic gaze, threads through earlier tantric and yogic teaching. These traditions held that holding the eyes still on a fixed point stilled the mind and opened inner perception. Brainspotting itself makes no claim of descent from these lineages and was created far more recently: psychotherapist David Grand developed it in the United States in 2003. Grand reports he built it directly out of Eye Movement Desensitization and Reprocessing (EMDR, Francine Shapiro, US, late 1980s), itself layered over psychoanalysis and Peter Levine's Somatic Experiencing, by way of a transitional method Grand called Natural Flow EMDR.
The deep history belongs to fixed-gaze practice in India, where the Hatha Yoga Pradipika and Gheranda Samhita codified trataka, steady unblinking gaze at a single point, as a cleansing and concentration technique centuries before any clinical eye-position therapy existed, alongside the broader concept of drishti. Brainspotting's own, much shorter, lineage runs through late-twentieth-century Western trauma work. Francine Shapiro introduced EMDR in the United States in the late 1980s. David Grand trained in psychoanalysis in the 1980s and in EMDR in 1993, blended it with Somatic Experiencing into a method he called Natural Flow EMDR, and in 2003, while working with survivors of the September 11 attacks, reported observing that a client's eyes seemed to lock and flutter at a particular gaze point tied to deep emotion. He named that point the brainspot. From there Grand built a trademarked training enterprise that has since reached thousands of clinicians across many countries, with the research base lagging well behind the spread of the method.
- ~15th c.Hatha Yoga Pradipika codifies trataka, fixed-point gazing, as a yogic cleansing and concentration practice in India; drishti concept already established
- Late 1980sFrancine Shapiro introduces EMDR in the United States, the immediate methodological parent of Brainspotting
- 2003David Grand reports identifying the first 'brainspot' while treating 9/11 survivors and names the method Brainspotting
- 2017Hildebrand, Grand, and Stemmler publish a multinational comparison reporting Brainspotting reduces PTSD symptoms comparably to EMDR
- 2022D'Antoni et al. (Italy) report Brainspotting and EMDR outperform body-scan and placebo conditions, but in short sessions with non-clinical participants
How it is understood
No living-tradition sovereignty claim attaches to Brainspotting. It is a contemporary commercial psychotherapy method with trademarked training, not an extraction from a closed or ceremonial practice. The ancient Indian gaze traditions named in the lineage are offered as documented historical antecedents of the broader idea that fixed gaze alters inner state, not as sources Brainspotting draws from or represents.
Where scholars disagree
Brainspotting's clinical finding (some clients improve) and its mechanistic theory (a fixed eye position corresponds to a subcortical site storing trauma) are separate claims with very different support. The clinical signal is preliminary but not implausible; the mechanism is contested and unvalidated.
David Grand and Brainspotting proponents and trainers
Relevant eye positions ('brainspots') directly access and help discharge trauma held in subcortical, midbrain-level structures, explaining rapid change that talk-based therapy cannot reach.
What it rests onClinician observation of consistent gaze 'reflexes' and reported symptom relief; naturalistic and pilot comparisons (Hildebrand 2017; D'Antoni 2022) reporting effects comparable to EMDR and better than control conditions.
Independent psychologists and reviewers (e.g. critiques noting it 'lacks scientific credibility, lacks clear testable mechanisms'; APA non-listing)
There is no validated neural basis for a gaze-to-trauma-site mapping; any benefit is better explained by shared, nonspecific factors (attention, interoception, exposure, therapeutic alliance) common to many therapies.
What it rests onAbsence of independent neuroscience confirming the proposed mechanism; small, allegiance-prone study base; APA does not list Brainspotting as a recommended PTSD treatment.
This disagreement is live. It has not settled.
At a glance
- Originator and year
- David Grand, United States, 2003, as an offshoot of EMDR
- Core premise
- 'Where you look affects how you feel'; a fixed eye position ('brainspot') is said by proponents to access stored trauma
- Evidence status
- Limited and preliminary; small/pilot and originator-involved studies; not APA-listed for PTSD
- Reach
- Thousands of clinicians trained internationally through a trademarked training program
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Brainspotting. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.